GLP-1 / GIP DUAL AGONIST

the GLP-1 / GIP dual agonist is a 39-amino-acid synthetic peptide that activates the GLP-1 and GIP receptors simultaneously. It is the first dual-incretin agonist marketed in the United States.

Same molecule, different label. the FDA-approved class member is FDA-approved for type 2 diabetes (May 2022). the FDA-approved class member is the same compound rebranded for chronic weight management (Nov 2023). Different concentrations and titration schedules per label.

Head-to-head data from SURPASS-2 show the GLP-1 / GIP dual agonist 15 mg outperformed the long-acting GLP-1 agonist 1 mg on HbA1c (-2.30% vs -1.86%) and produced larger weight loss. Comparisons at higher the long-acting GLP-1 agonist doses (2.4 mg) are also published; the GLP-1 / GIP dual agonist retains an edge on average.

Per FDA label, the GLP-1 / GIP dual agonist is titrated weekly: 2.5 mg starting → 5 mg → up to 15 mg over months. This wiki reproduces the label dose schedule for reference only; any human use should be under qualified clinical supervision.

Approximately five days, enabled by a C20 fatty-acid linker on a modified GIP backbone that drives albumin binding and slow clearance.

FDA declared the the GLP-1 / GIP dual agonist shortage resolved October 2024, restricting compounding under section 503A. Research-grade the GLP-1 / GIP dual agonist sold as a chemical reference compound is distinct from compounded human-use formulations and is supplied here for in-vitro research only.

Class-based rodent C-cell tumor signal led to a boxed warning. Translation to human relevance is debated; current clinical data have not established a causal link, but personal or family history of medullary thyroid carcinoma is a contraindication.

No published research supports simultaneous use of multiple incretin agonists. The pathways overlap and combined use is unstudied.

GLP-1R agonism drives glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite suppression. GIPR agonism enhances post-prandial insulin and modulates adipocyte lipid handling. Combined activation produces larger absolute weight loss than single-receptor agonism.

In SURMOUNT-1, mean weight loss followed a curve: ~2-3% by week 4, ~10% by week 24, ~20% by week 72 at the highest dose arm. Individual response varies significantly.

SURMOUNT-4 (re-randomization) showed cessation produces partial weight regain over 52 weeks. Continued treatment is required for maintenance of the loss.

Not currently on the WADA Prohibited List as of 2026. Status reviewable annually.

The active molecule is the same. Branded human-prescription products are formulated, labeled, and quality-controlled to FDA pharmaceutical standards under separate clinical pathways. Research-grade material is a chemical reference compound for laboratory use only.

The SURMOUNT-OSA program reported significant reductions in the apnea-hypopnea index (AHI) in adults with moderate-to-severe obstructive sleep apnea and obesity treated with the GLP-1 / GIP dual agonist. FDA approved the GLP-1 / GIP dual agonist (the FDA-approved class member) for moderate-to-severe OSA in adults with obesity in December 2024. Mechanism is thought to be a combination of direct weight-loss effects and indirect effects on upper-airway tissue.